Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.
OBJECTIVE
To evaluate the ocular complications of intravitreal injection of high dose bevacizumab in monkey eyes.


METHODS
Four healthy monkeys (Macaca fuscata) received an intravitreal injection of either 6.25 or 12.5 mg bevacizumab in the right eye; the left control eye received an intravitreal injection of the same volume of saline. The eyes were examined using slit lamp and funduscopy, optical coherence tomography (OCT), electroretinography (ERG), fundus photography (FP), fluorescein angiography (FA), and indocyanine green angiography (ICGA). The eyes were enucleated 28 days after the intravitreal injection and subjected to light microscopy.


RESULTS
No pathologic changes were observed by FP, FA, ICGA, OCT, and light microscopy in the eyes injected with either of the two bevacizumab doses. ERG showed no toxic change in the eyes that received the 6.25-mg dose. In two eyes that received the 12.5-mg dose, ERG showed no significant difference between the right and left eyes 4 weeks after injection, although there were transient changes in scotopic responses.


CONCLUSIONS
No irreversible toxic effects were observed in monkey eyes receiving an intravitreal injection of high dose bevacizumab.
Sakurai
Kenji
K
Department of Ophthalmology, Gunma University School of Medicine, Gunma, Japan.
Akiyama
Hideo
H
Shimoda
Yukitoshi
Y
Yoshida
Izumi
I
Kurabayashi
Masahiko
M
Kishi
Shoji
S
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000633:toxicity*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004396:Coloring Agents; D004596:Electroretinography / Q000187:drug effects; D005260:Female; D005451:Fluorescein Angiography; D007208:Indocyanine Green; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008252:Macaca fascicularis; D008297:Male; D009887:Ophthalmoscopy; D012160:Retina / Q000187:drug effects* / Q000502:physiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green